发明名称 |
METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS |
摘要 |
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug. |
申请公布号 |
HK1208250(A1) |
申请公布日期 |
2016.02.26 |
申请号 |
HK20150108958 |
申请日期 |
2015.09.14 |
申请人 |
THE GENERAL HOSPITAL CORPORATION |
发明人 |
DAPHNE WINIFRED BELL;DANIEL A. HABER;PASI ANTERO JANNE;BRUCE E. JOHNSON;THOMAS J. LYNCH;MATTHEW MEYERSON;JUAN GUILLERMO PAEZ;WILLIAM R. SELLERS;JEFFREY E. SETTLEMAN;RAFFAELLA SORDELLA |
分类号 |
C12Q;C12N;C12Q1/48;C12Q1/68;G01N33/574;G01N33/74 |
主分类号 |
C12Q |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|